Dravet syndrome is a severe, early-onset epileptic encephalopathy frequently resulting from de novo mutations of SCN1A. Mice with heterozygous deletion of Scn1a (Scn1a ences were more pronounced, with dozens of genes with > 1.5-fold expression differences between 129 and F1 strains. Age-specific and seizure-related gene expression differences were most prominent, with hundreds of genes with > 2-fold differences in expression identified between groups with and without seizures, suggesting potential differences in developmental trajectory and/or homeostatic plasticity during disease onset. Global expression differences in the context of Scn1a deletion may account for strain-dependent variation in seizure susceptibility and survival observed in Scn1a +/− mice.
Introduction
Dravet syndrome is an infant-onset epileptic encephalopathy frequently associated with a poor prognosis. Individuals with Dravet syndrome exhibit various types of seizures, as well as comorbid psychomotor and cognitive delays, and have a significant risk for sudden unexplained death in epilepsy (SUDEP) (Dravet, 2011; Dravet and Oguni, 2013) . Over 80% of individuals diagnosed with Dravet syndrome have a mutation in SCN1A, with nearly all variants arising de novo (Claes et al., 2009 ). The majority of SCN1A mutations identified in Dravet syndrome are nonsense, frameshift, or splice site mutations that result in protein truncation, while the remaining missense mutations are believed to result in loss of protein function (Claes et al., 2009; De Jonghe, 2011; Scheffer et al., 2009 ). This suggests that SCN1A haploinsufficiency is responsible for Dravet syndrome.
Mouse models of Dravet syndrome have been generated by disruption of the Scn1a gene Yu et al., 2006) . Mice with heterozygous deletion of Scn1a (Scn1a +/− ) recapitulate many features of Dravet syndrome, including spontaneous generalized tonicclonic seizures, seizures provoked by hyperthermia and premature lethality Kalume et al., 2013; Yu et al., 2006) . A common feature of epilepsy mouse models, including the Scn1a +/− Dravet model, is strain-dependent differences in pheno-in F1.Scn1a +/− than 129.Scn1a +/− (Mistry et al., 2014) . These observations suggested the B6 strain contributed modifier alleles that influence penetrance and severity of the Scn1a +/− Dravet phenotype.
Using QTL mapping, we identified multiple modifier loci (Dsm1-5, Dravet syndrome modifier) which influence strain-dependent survival of Scn1a +/− mice . One locus of interest, Dsm1, was fine-mapped and Gabra2 was identified as a putative modifier gene by comparing C57BL/6 J and 129S6/SvEvTac gene expression in forebrain by RNA-seq . RNA-seq analysis has been a useful tool for identifying epilepsy modifier genes following positional cloning in various epilepsy mouse models, (Calhoun et al., 2016 (Calhoun et al., , 2017 Hawkins and Kearney, 2012, 2016; Thompson et al., 2017) . However, the mapped modifier loci do not account for the full range of phenotypic variance. Therefore, in this study we globally characterized hippocampal gene expression in Scn1a +/− and WT mice on both the [129S6 X B6]F1 susceptible and 129S6 resistant strains at postnatal day (P) 14 and P24, during the critical time window of disease onset. The P24 F1.Scn1a +/− cohort was further subdivided into mice with and without spontaneous seizures in the 24 h prior to collection. In the absence of seizures, more genes were differentially expressed between the two strains and ages of mice rather than between Scn1a genotypes. As anticipated, RNA-seq analysis identified numerous changes in gene expression following seizures in the P24 F1.Scn1a +/− cohort with seizures within 24-h of sample collection.
Materials and methods

Mice
Scn1a tm1Kea mice were generated by homologous recombination in were maintained in a Specific Pathogen Free (SPF) barrier facility with a 14-h light/10-h dark cycle and access to food and water ad libitum. Mice were genotyped by PCR as previously described . All animal care and experimental procedures were approved by the Northwestern University Animal Care and Use Committees in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Seizure monitoring
Prior to euthanasia on P24, F1.Scn1a +/− mice were monitored for spontaneous generalized tonic-clonic seizures (GTCS) by continuous video-monitoring as previously described Hawkins et al., 2017; . Briefly, mice were placed in a recording chamber (28 × 28 × 36 cm) and overhead video was captured using a Day/Night camera equipped with an infrared lens. During recording, mice had ad libitum access to food and water, and were maintained on a 14:10 light-dark cycle. Digital video images captured during the video-monitoring session were analyzed offline for the occurrence of spontaneous GTCS prior to pooling of tissue for RNA isolation. Previous video-EEG monitoring of F1.Scn1a +/− mice showed a perfect correlation between behavioral and electroencephalographic seizures (κ = 1.0), supporting non-invasive video monitoring as a reliable assay for GTCS detection .
RNA sample preparation
Hippocampi were dissected from 129 and F1 WT and Scn1a +/− mice at P14 and P24. Primary pools for all groups without seizures were created by combining tissue from both males (n = 2) and females (n = 2). For the P24 seizure cohort, primary pools were created by combining tissue from 3 or 4 mice (at least one from each sex) with seizure counts ranging from 3 to 7 in the 24 h prior to collection. Mice that had one or two GTCS prior to collection were excluded from the study. Total RNA was isolated using TRIzol reagent according to the manufacturer's instructions (Life Technologies). Following RNA isolation, RNA integrity was assessed and all samples had a RIN of ≥7.7. For each group without seizures, 2-3 superpooled biological replicates were generated by combining total RNAs from 3 to 4 primary pools (n = 12-16 mice/superpool) (Fig.1A) . For the P24 seizure cohort, the primary pools were used as biological replicates (n = 3-4 mice/ sample). RNA integrity was measured on the superpool samples and all samples had RIN of ≥8.1.
RNA-Seq
Samples were processed for RNA-Seq using the TruSeq RNA Library Preparation Kit v2 (Illumina, San Diego, CA, USA). Samples were sequenced on an Illumina HiSeq 4000 at BGI (Hong Kong, China). Three multiplexed lanes of 50-bp single-end sequencing resulted in almost 167 million mapped reads. Base calling and filtering of sequence reads were performed with the Illumina pipeline (Bentley et al., 2008) . Bioinformatic analysis was performed on the GALAXY platform (Afgan et al., 2010; Blankenberg et al., 2010; Giardine et al., 2005) . FastQ files were groomed using FastQ groomer (v. 1.0.4) aligned to the mm10 mouse genome with Tophat2 (v. 2.1.0) (Kim et al., 2013) . Counts were calculated with HTSeq (union overlap mode; v. 0.6.1p1) and differential expression was assessed with DESeq2 (v. 2.11.38) (Love et al., 2014) . Differentially expressed genes were clustered based on log 2 (normalized expression) and heatmaps were generated using gplots for R. Gene sets were evaluated for intersections using Venny (v. 2.1.0) (Oliveros, 2007 (Oliveros, -2015 , mammalian phenotype (MP) ontology, gene ontology (GO) and pathway enrichment using MouseMine (hypergeometric distribution with Holm-Bonferroni correction) and functional and protein-protein interaction enrichment using STRING (v. 10.5) (FDR adjusted P-values) (Motenko et al., 2015; Szklarczyk et al., 2017) .
RNA-seq data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE112627 (https://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE112627).
ddRT-PCR
First-strand cDNA was synthesized from 2 micrograms of total RNA using oligo(dT) primer and Superscript IV reverse transcriptase according to the manufacturer's instructions (Life Techologies). First-strand cDNA samples were diluted to be within the linear range for each assay based on empirical determination with serial dilution. Quantitative droplet digital PCR (ddPCR) was performed using ddPCR Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA, USA) and TaqMan Assays as previously described . Taqman gene expression assays (Life Technologies) were:
Relative transcript levels were expressed as a concentration ratio of the gene of interest to Tbp (Aspg, Blnk, Cdkn1a, Gal, Gldn, Prss23, Serpine1, Timp1) or Gapdh (Gfap, Vim).
Immunoblotting
Hippocampal protein was isolated from P24 mice following seizure monitoring as described above. Proteins (50 μg per lane) were separated on a 7.5% SDS-PAGE gel and transferred to nitrocellulose membranes. Immunoblots were probed for GFAP using a rabbit polyclonal antibody (1:500; G9269, Sigma Aldrich) and for Mortalin using a mouse monoclonal antibody (1:1000; NeuroMab, clone 75-127). Alexa-conjugated fluorescent anti-rabbit 790 and anti-mouse 680 secondary antibodies (Jackson ImmunoResearch; 1:20,000) were used to detect bound primary antibody using an Odyssey imaging system (Licor).
Relative protein levels were determined by densitometry using ImageStudio software (Licor) and expressed as a ratio of GFAP to antimortalin, with n = 3 biological replicates.
cFos immunhistochemistry
F1.Scn1a
+/− mice were continuously video monitored from P21-P25 as described above. Video was rapidly reviewed multiple times per day to identify seizures and schedule perfusions post-seizure. Control tissue was obtained from F1.Scn1a +/− littermates confirmed on video to have not experienced a seizure in a minimum of 4-7 h preceding samples comprising the nine experimental groups. Dissected hippocampi from 4 animals (2 male, 2 female) were pooled prior to RNA isolation. Following RNA isolation, 3-4 samples with RIN > 7.6 were combined to generate superpools (n = 12-16 mice/superpool). For RNA-seq analysis 2-3 superpool biological replicates were used for each group. The number of replicates is shown in the lower left corner of the box representing the experimental groups. P24 F1.Scn1a +/− samples were further subdivided into two groups: without seizures (no shading), or with ≥3 seizures (yellow shading) within 24 h of sample collection. B&C) Sample-to-sample distances visualized by principal component analysis for experimental groups with exclusion (B) or inclusion (C) of F1.Scn1a +/− mice with seizures. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) N.A. Hawkins et al. Experimental Neurology 311 (2019) 247-256 perfusion. Mice were deeply anesthetized with Euthasol (100 mg/kg, intraperitoneal) and transcardially perfused with 0.1 M phosphate buffer followed by 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were removed and postfixed overnight, cryoprotected in 30% sucrose and sectioned at 40 μm. Free-floating coronal sections were processed for cFos immunoreactivity with primary rabbit anti-c-Fos antibody (Cell Signaling Technology #2250; 1:3000). Signal was visualized using a VECTASTAIN Elite ABC HRP Kit (Vector Labs; PK-6101) and. Signal was detected using 3,3′-Diaminobenzidine tetrahydrochloride with CoCl 2 enhancement (Sigma-Aldrich # D0426). Sections were imaged on a TissueGnostics imaging platform with a 20× objective with automated image stitching.
Results
On the 129S6/SvEvTac (129) Overall, principal component analysis and hierarchical clustering indicated that strain and age had a more profound effect on variance than genotype in the absence of recent seizures, while inclusion of the seizure-positive group (≥3 seizures within 24-h) had a strong effect on variance (Fig. 1B-C) .
Genotype-specific gene expression differences
At P14 before symptom onset, there were no hippocampal DEGs between 129.WT and 129.Scn1a +/− mice and only 21 DEGs with modest differences between F1.WT and F1.Scn1a Table 2 ). Although the modest differences were only 6-12%-fold change, they are enriched in MP and GO terms relevant to the phenotype, including "seizures" [MP:0002064] and 'ion transport' and 'ion homeostasis' pathways ( Fig. 2A-B) . A similar pattern is observed at P24 with limited differences between genotypes. Only a single DEG, Scn1a, was identified between 129.WT and 129.Scn1a +/− mice on the protective 129 strain. On the F1 strain, P24 F1.WT and F1.Scn1a +/− mice without recent seizures had 80 DEGs with 1.12 to 1.36-fold differences ( Fig. 2A; Supplementary Table 2 ). Again, although the differences are modest, they are enriched in MP and GO terms relevant to the phenotype ( Fig. 2C ; Supplementary Table 2 ). The observed gene expression differences between genotypes in F1 mice at P14 and P24 did not share any overlap.
Strain-specific gene expression differences
At P14, the number of hippocampal DEGs with a ≥ 1.5-fold change between 129 and F1 strains is similar in WT and Scn1a +/− mice, with 17 and 16 genes, respectively ( Fig. 3A-B ; Supplementary Table 3) . At P24, WT mice had 41 DEGs with ≥1.5-fold difference in hippocampal expression between the 129 and F1 strains, while Scn1a +/− mice without recent seizures had ≥1.5-fold differences in 25 genes − ( Fig. 3A-B ; Supplementary Table 3) . At both ages, strain DEGs included 12 shared differences in genes encoding mainly ribosomal proteins with enrichment for protein-protein interactions (STRING PPI enrichment p = 0.00211) (Fig. 3B-C) .
Age-specific gene expression differences
Next we compared developmental gene expression differences between P14 and P24 within the same strain and genotype in the absence of recent seizures. As expected, there were a significant number of ≥2-fold DEGs between ages for all groups, including a core set of 64 shared genes enriched for the GO term 'nervous system development' [GO:0007399; p = 0.01126] ( Fig. 4A-B ) ( Fig. 4B-C ; Supplementary Table 4 ).
Seizure related gene expression differences
Seizure onset in F1.Scn1a
+/− mice occurs between P16-19 Table 5) . Of those, 100 were shared differences that we defined as a core set of seizure-induced DEGs ( Fig. 5A ; Supplementary Table 5) . We compared this core set of seizureinduced DEGs with a recent set of published DEGs in another genetic epilepsy mouse model, Scn8a
N1768D/+ , with and without seizures, as well as with rodent induced-seizure models compiled from the literature (Dingledine et al., 2017; Sprissler et al., 2017) . Differential expression of 26 genes was observed in at least two of three DEG sets, and 10 DEGs were shared across all three sets (Aspg, Blnk, Cdkn1a, Gal, Gfap, Gldn, Prss23, Serpine1, Timp1, Vim) (Fig.5B) ) (Fig. 5D) . The central node of this protein-protein interaction pathway is the immediate early gene Fos, which is strongly activated in the hippocampus at 1-3 h following a spontaneous seizure in Scn1a +/− mice (Fig. 5E ).
Discussion
We previously reported strain-dependent differences in phenotype expressivity in the Scn1a +/− Dravet model ). In the current study we profiled global hippocampal gene expression across different genotypes, strains and ages to assess potential transcriptional differences that may underlie the observed strain-dependence of the Scn1a +/− Dravet model. This analysis included examining gene expression differences by genotype, strain, age, and seizure status. Overall, the magnitude of gene expression differences between genotypes was modest, between strains was moderate, and between age or seizure status were largest. The specific comparisons and their potential implications are discussed in more detail below.
Genotype-specific gene expression differences
Remarkably, there were no differences in gene expression between the protective 129 strain background may be buffered against transcriptional changes in the context of heterozygous deletion of Scn1a. In contrast, on the susceptible F1 strain, there were modest differences in gene expression at P14 and P24. Although the differences were small, ranging from 6 to 12%-fold change at P14 and 12-36%-fold change at P24, gene set enrichment analysis demonstrated enrichment in GO and MP terms relevant to the phenotype, including synaptic signaling, neurodevelopment, abnormal nervous system physiology and seizurerelated terms, among others. This accumulation of modest changes in a collection of relevant genes may potentially reflect homeostatic plasticity mechanisms that attempt to rebalance neuronal excitability in response to Scn1a +/− deletion in the F1 strain. It is also possible that the limited number and small magnitude of genotype-specific differences may result from dampening of signals from minor cells types within the bulk hippocampal tissue. Future gene expression studies of isolated hippocampal cell types will investigate this possibility. Interestingly, the only observed change in expression of other voltage-gated sodium channel genes was a modest 11% difference in Scn2a expression between P14 F1.Scn1a
+/− and F1.WT mice. Previous reports of Scn8a medtg and Scn8a medJ null and hypomorphic alleles have demonstrated compensatory actions of Nav1.1 and Nav1.2 at the protein level, but there is no evidence of corresponding transcriptional upregulation of Scn1a and Scn2a (Kearney et al., 2002; Van Wart and Matthews, 2006; Vega et al., 2008) .
Strain-specific gene expression differences
There were a total 49 genes with ≥1.5-fold differential expression between 129 and F1 strains. Notable among these was Gabra2, which we previously identified as a genetic modifier that influences the Scn1a +/− survival phenotype . Strain-specific DEGs included 12 differences shared across both ages and genotypes (Fig. 3B ). These shared differences were enriched for genes encoding ribosomal proteins (Fig. 3C ). Differential and dynamic expression of ribosomal protein has been previously reported across developmental stages, raising the possibility that F1 and 129 mice may differ in hippocampal developmental trajectory between P14 and P24 (Kondrashov et al., 2011; Kraushar et al., 2016; Perucho et al., 2014) . N.A. Hawkins et al. Experimental Neurology 311 (2019) 247-256 
Age-specific gene expression differences
We observed a significant number of ≥2-fold DEGs between P14 and P24, as expected, including a shared set of 64 core genes enriched for the GO term 'nervous system development'. While 129.Scn1a +/− and 129.WT had relatively few unique DEGs between P14 and P24, F1.WT and F1.Scn1a +/− had 52 and 21 unique DEGs, respectively.
Although there was no significant term enrichment in the F1.Scn1a
+/− group, F1.WT DEGs were enriched for the GO terms 'cell cycle' and 'cell cycle process' and for protein-protein interactions. The pattern of DEG enrichment suggests upregulation of mitotic activity and neurogenesis in the F1.WT mice from P14 to P24. This again raises the possibility that F1.WT and 129.WT mice may differ in hippocampal developmental trajectory in the third week of life.
Seizure related gene expression differences
As expected, spontaneous seizure activity induced many changes in gene expression. We observed 113 ≥ 2-fold DEGs between P24
F1.Scn1a
+/− mice with and without seizures in the antecedent 24 h.
Further comparison with F1.WT mice and 129.Scn1a +/− mice allowed us to define a core set of 100 seizure-induced DEGs. Comparison of our core set of seizure-induced DEGs with DEG sets from another genetic epilepsy model, Scn8a N1768D/+ and rodent-induced seizure models, identified a set of 10 DEGs that were shared among these models.
Although there was only a 10% overlap of specific DEGs, there are numerous differences between the models, including age of seizure onset, strain background and species (mouse vs. rat), as well as RNA preparation, evaluation and analysis platforms. Thus, these 10 DEGs represent the most robust seizure-induced changes and may serve as broad candidates for neuroprotection. Half of the shared DEGs are associated with astrogliosis (Zamanian et al., 2012; Zhang et al., 2016) , and consistent with this we observed a trend toward increase GFAP protein in the hippocampus of F1.Scn1a +/− mice with seizures relative to those without seizures in the antecedent 24 h (Fig. S2) . Overall, this robust set of shared DEGs includes genes known to be elevated in response to seizures or traumatic brain injury in human and rodent models ( N.A. Hawkins et al. Experimental Neurology 311 (2019 ) 247-256 et al., 2015 Samal et al., 2015; Sprissler et al., 2017) . This suggests that these changes are a consequence of the insult rather than a cause, but it is not possible to parse whether these expression alterations are adaptive or maladaptive based on gene expression studies alone. We also compared developmental changes from P14 to P24 between F1.Scn1a +/− mice with and without seizures, following exclusion of N.A. Hawkins et al. Experimental Neurology 311 (2019) 247-256 acute seizure-induced DEGs in order to separate injury induced changes from potential homeostatic changes. This analysis revealed 68 shared DEGs versus 163 unique DEGs with seizures, or 49 unique DEGs without seizures. Shared DEGs were enriched for 'nervous system development', 'cell development' and 'gliogenesis' GO terms, consistent with expectations as mouse hippocampus continues to develop between P14 and P24. Interestingly, the DEG set unique to F1.Scn1a +/− mice with seizures (excluding acute seizure-induced DEGs discussed above) was enriched for signaling/plasticity related KEGG pathways, including 'calcium signaling pathway' and 'neuroactive ligand-receptor interaction', suggesting that homeostatic plasticity occurs in the hippocampus in response to seizure activity. This is consistent with the long-standing hypothesis that homeostatic plasticity occurs in response to seizure activity and/or brain injury, and failure of these mechanisms to adequately rebalance excitability contributes to the development and progression of epilepsy.
Conclusion
Our previous modifier mapping studies relied on RNA-seq comparisons between WT mice of the resistant and permissive background strains. This revealed intrinsic strain differences, but did not account for differences in strain response to the primary driver mutation. Here we used gene expression profiling to characterize genome-wide differences in the context of the driver mutation which may reveal additional modifiers that contribute to the variable phenotype of Scn1a +/− mice.
Furthermore, this analysis may suggest additional genes which influence seizure manifestation, independent of the previously identified Dravet survival modifier loci . Future studies will evaluate the contribution of unique DEGs identified between F1. Scn1a +/− mice with and without seizures that are related to acute seizure activity to determine whether they influence presentation or frequency of seizures in the Scn1a +/− Dravet mouse model.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.expneurol.2018.10.010.
